학술논문
Remibrutinib, a Novel Highly Selective and Potent BTKi in Development for MS: Analysis of Safety Data From the Completed Phase 2 Studies in Other Inflammatory Immune-Mediated Diseases
Document Type
Journal
Author
Chitnis, Tanuja; Williams, Mitzi; Airas, Laura; Saini, Sarbjit; Hide, Michihiro; Sussman, Gordon; Nakahara, Jin; Bermel, Robert; Doerner, Thomas; Loop, Brett; Delasheras, Virginia; Willi, Roman; Kieseier, Bernd C.; Haemmerle, Sibylle; Zharkov, Artem; Siegel, Richard; Cenni, Bruno; Wiendl, Heinz; Maurer, Marcus; Gimenez-Arnau, Ana; Montalban, Xavier
Source
Subject
Language
English
ISSN
14770970